BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35688064)

  • 1. Who are the real high-risk patients with pathological T2N0M0 non-small-cell lung cancer that can benefit from adjuvant chemotherapy?
    Hou X; Yang MZ; Li JB; Tan ZH; Long H; Fu JH; Zhang LJ; Lin P; Yang HX
    ESMO Open; 2022 Jun; 7(3):100508. PubMed ID: 35688064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk stratification and adjuvant chemotherapy after radical resection based on the clinical risk scores of patients with stage IB-IIA non-small cell lung cancer.
    Zhai W; Duan F; Li D; Yan Q; Dai S; Zhang B; Wang J
    Eur J Surg Oncol; 2022 Apr; 48(4):752-760. PubMed ID: 34620508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non-small cell lung cancer.
    Zhang P; Duan J; Bai H; Wang Z; Gao S; Tan F; Gao Y; Wang X; Wan R; Xu J; He X; Feng X; Yu R; Sun J; Zhao Z; Fei K; Li N; He J; Wang J
    Thorac Cancer; 2021 Jan; 12(1):30-39. PubMed ID: 33111432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propensity-matched analysis of adjuvant chemotherapy for completely resected Stage IB non-small-cell lung cancer patients.
    Li X; Zhang C; Sun Z; Yang F; Xiao R; Sui X; Jiang G; Zhong W; Wang J
    Lung Cancer; 2019 Jul; 133():75-82. PubMed ID: 31200832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Population-based Impact of Adjuvant Chemotherapy on Outcomes in T2N0M0 Non-Small Cell Lung Cancer.
    Arora RK; Gibson AW; Bebb DG; Cheung WY
    Am J Clin Oncol; 2020 Jul; 43(7):496-503. PubMed ID: 32349021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
    Yang H; Wang K; Li S; Li Y; Yuan L
    Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
    [No Abstract]   [Full Text] [Related]  

  • 8. Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.
    Xie H; Wang H; Xu L; Li M; Peng Y; Cai X; Feng Z; Ren W; Peng Z
    Clin Lung Cancer; 2018 Nov; 19(6):484-492. PubMed ID: 30369426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis.
    Raphael J; Vincent M; Boldt G; Shah PS; Rodrigues G; Blanchette P
    Am J Clin Oncol; 2019 May; 42(5):440-445. PubMed ID: 30913091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of adjuvant chemotherapy on survival for patients with completely resected high-risk stage IB NSCLC.
    Shen ZQ; Feng KP; Fang ZY; Xia T; Pan S; Ding C; Xu C; Ju S; Chen J; Li C; Zhao J
    J Cardiothorac Surg; 2024 Jan; 19(1):1. PubMed ID: 38166960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC.
    Morgensztern D; Du L; Waqar SN; Patel A; Samson P; Devarakonda S; Gao F; Robinson CG; Bradley J; Baggstrom M; Masood A; Govindan R; Puri V
    J Thorac Oncol; 2016 Oct; 11(10):1729-35. PubMed ID: 27287414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of adjuvant chemotherapy for patients with pT2N0M0 non-small cell lung cancer receiving radical resection.
    Chen S; Yang S; Zhao Y; Zhang Y; Huang Q; Wu H; Hu H; Sun Y; Zhang Y; Xiang J; Ye T; Chen H
    Thorac Cancer; 2024 Jan; 15(3):258-265. PubMed ID: 38098268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer.
    Cheng H; Li XJ; Wang XJ; Chen ZW; Wang RQ; Zhong HC; Wu TC; Cao QD
    Lung Cancer; 2019 Nov; 137():7-13. PubMed ID: 31520922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.
    Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Wei YC; Liu YY; Chen C; Cheng Y; Yin R; Yang F; Ren SX; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yang JJ; Yan HH; Yang XN; Liu SY; Zhou Q; Wu YL
    J Clin Oncol; 2021 Mar; 39(7):713-722. PubMed ID: 33332190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
    Wen M; Wang L; Wang X; Yang S; Sun Y; Xia J; Zhang Y; Zhang Z; Huang L; Jiang T
    Oncol Res Treat; 2020; 43(12):686-693. PubMed ID: 33197924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of postoperative radiotherapy after curative resection and adjuvant chemotherapy for patients with pathological stage N2 non-small-cell lung cancer: a propensity score matching analysis.
    Kim BH; Kim HJ; Wu HG; Kang CH; Kim YT; Lee SH; Kim DW
    Clin Lung Cancer; 2014 Sep; 15(5):356-64. PubMed ID: 24996882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
    Zhao P; Zhen H; Zhao H; Zhao L; Cao B
    BMC Cancer; 2022 Mar; 22(1):328. PubMed ID: 35346117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of age on adjuvant chemotherapy after radical resection in patients with non-small cell lung cancer.
    Zhai X; Yang L; Chen S; Zheng Q; Wang Z
    Cancer Med; 2016 Sep; 5(9):2286-93. PubMed ID: 27367482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of EGFR-TKIs as adjuvant therapy in EGFR mutation-positive early-stage NSCLC: A meta-analysis.
    Lin C; Hu F; Chu H; Ren P; Ma S; Wang J; Bai J; Han X; Ma S
    Thorac Cancer; 2021 Apr; 12(7):1084-1095. PubMed ID: 33660941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.